Core Insights - ZenaTech, Inc. has established a new Quantum Computing Division aimed at developing advanced computing solutions for defense and autonomous drone systems [1][3] - The division will focus on quantum innovations for secure communications, navigation without GPS, and AI optimization for drone fleets in defense applications [2][3] Company Overview - ZenaTech specializes in AI drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, serving mission-critical business applications [7] - The company has been operational since 2017, enhancing its drone design and manufacturing capabilities through ZenaDrone, and has a diverse customer base across various sectors including law enforcement, health, government, and agriculture [7] Quantum Computing Division - The Quantum Computing Division will expand its current team from 12 to 20 by year-end, incorporating experts in AI, machine learning, quantum hardware, and computational sciences [3] - The division will also advance two existing Quantum R&D projects: Sky Traffic, which optimizes traffic flows using AI-enabled drones, and Clear Sky, which improves weather forecasts through AI drone swarms [4] Product Offerings - The ZenaDrone 1000 is a medium-sized VTOL drone capable of carrying up to 40kg, designed for various applications including defense, agriculture, and inspections [5] - The drone features AI-enabled autonomy and secure communications, and has undergone paid trials with the US Air Force and Navy Reserve [5] Industry Context - The US Department of Defense is prioritizing advancements in quantum-resistant communications and quantum sensing for drone navigation, aligning with ZenaTech's focus on these areas [2] - Quantum computing is recognized as a transformative technology that can solve complex problems beyond the capabilities of classical computers, enhancing data processing and analysis for drone applications [6]

More women turn to technology solutions, with 71% looking to discreet devices for safetyLOUISVILLE, Ky., Aug. 19, 2025 (GLOBE NEWSWIRE) -- A comprehensive new national survey commissioned by LogicMark, Inc. (OTC: LGMK), a provider of personal safety devices, related to women’s safety exposes a stark reality: walking alone at night dominates their concerns, with 67% of respondents identifying it as their primary fear –- significantly outpacing traveling in unfamiliar areas (55%) or navigating parking garages ...

MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that it closed an underwritten public offering of 1,000,000 shares of its common stock, par value $0.001 per share, at a price of $4.00 per share. The shares of common stock commenced trading on the Nasdaq Capital Market on August 15, 2025, under ...

Core Viewpoint - Mercurity Fintech Holding Inc. successfully closed a private placement financing, raising approximately US$6.0 million in gross proceeds to enhance its Digital Asset Treasury strategy and strengthen its balance sheet [1][2][3]. Group 1: Financing Details - The private placement involved securities purchase agreements with institutional investors, resulting in total gross proceeds of about US$6.0 million before deducting offering expenses [1]. - The net proceeds from this financing will be utilized to advance the Company's Digital Asset Treasury strategy, providing financial flexibility for growth opportunities in the digital asset landscape [2]. Group 2: Management Commentary - CEO Shi Qiu expressed satisfaction with the completion of the private placement, highlighting the recognition of the Company's value proposition by strong institutional investors [3]. - The funding is intended to support the execution of Digital Asset Treasury initiatives and drive long-term value for shareholders [3]. Group 3: Company Overview - Mercurity Fintech Holding Inc. operates as a fintech group leveraging blockchain infrastructure, offering technology and financial services through its subsidiaries [5]. - The Company aims to bridge traditional finance with digital innovation across various sectors, including digital asset management and capital markets solutions [5].

Q2 2025 Revenue Increased 22% Year-Over Year to $23.2 Million as Compared to Q2 2024CELEBRATION, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech company, today provided a business update and reported financial results for the for the second quarter ended June 30, 2025. Q2 2025 Financial Highlights Total revenue increased 22% year-over-year to $23.2 million for the second quarter ended June 30, 2025 from $19.1 million for ...

VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- HydroGraph Clean Power Inc. (CSE: ‎HG) (OTCQB: HGRAF) (the “Company” or “HydroGraph”), producer of one of the world’s highest purity graphenes, today announced the appointment of technology executive, military veteran and leadership coach Cordell Bennigson to its board of directors. Bennigson is currently CEO of R2 Wireless U.S., leading the expansion of spectrum sensing and electromagnetic dominance solutions for defense and critical infrastruc ...

Core Viewpoint - LEEF Brands, Inc. reported a pivotal transition in Q2 2025, highlighted by the completion of its first planting at Salisbury Canyon Ranch and the acquisition of a New York cannabis license, which are expected to enhance margins and open new revenue streams starting in Q3 2025 [4]. Financial Highlights - Revenue for Q2 2025 reached $8.7 million, a 10% increase from $7.9 million in Q2 2024, driven by a 19% year-over-year increase in unit sales [7]. - Gross margin was reported at 24%, down from 34% in Q2 2024, attributed to higher input costs for clean extraction material, with expectations for improvement as the company begins processing material from Salisbury Canyon Ranch in Q3 2025 [7]. - The net loss for the quarter was $2.9 million, or ($0.02) per share, reflecting a 45% improvement from a $5.5 million loss in Q2 2024 [7]. - Adjusted EBITDA was reported at ($1.2) million, compared to $0.3 million in Q2 2024, impacted by lower gross margins and increased operating expenses related to the planting at Salisbury Canyon Ranch and ramping operations in New York [7]. Operational Highlights - The company successfully planted Salisbury Canyon Ranch, one of the largest cannabis farms globally, and has harvested the material, with a second crop replanted for fall harvest [7]. - The summer harvest exceeded expectations and is anticipated to drive significant margin improvements beginning in Q3 2025 [7]. - The acquisition of a New York cannabis license on June 9, 2025, is expected to enable the company to produce a full range of concentrates starting in Q3 2025, contributing to increased revenue and margins [7]. - Josh Keats joined as Chief Operating Officer in June 2025, bringing over 20 years of cannabis industry experience, which is expected to enhance operational excellence as the company scales cultivation and enters new markets [7].

Core Viewpoint - The U.S. FDA has placed a clinical hold on BiomX's Phase 2b study of BX004 due to concerns regarding the third-party nebulizer device used for drug delivery, while the BX004 drug candidate itself has no concerns raised by the FDA [1][2][3] Group 1: Clinical Trial Status - The clinical hold is temporary, and BiomX has submitted additional data to the FDA to address the concerns regarding the nebulizer [2][3] - Patient screening and enrollment in the U.S. portion of the Phase 2b trial of BX004 have been paused, while enrollment and dosing continue in Europe where the nebulizer device meets regulatory requirements [2][4] Group 2: BX004 Development - BX004 is a fixed multi-phage cocktail targeting chronic pulmonary infections caused by Pseudomonas aeruginosa in cystic fibrosis patients [4] - Positive results from earlier studies indicate safety, tolerability, and improvement in pulmonary function associated with reduced bacterial load [4] - The Phase 2b trial aims to enroll approximately 60 patients and will assess lung function, bacterial load, and quality of life metrics over an 8-week period [4] Group 3: Company Overview - BiomX is focused on developing natural and engineered phage therapies to target specific pathogenic bacteria for chronic diseases with unmet needs [5] - The company utilizes its BOLT platform to customize phage compositions against proprietary bacterial targets [5]

MONROE TOWNSHIP, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT” or the “Company”), a leader in intelligent maritime solutions, today announced a major upgrade to its AI-capable Merrows™ Maritime Domain Awareness Solution (MDAS). The updated system expands its role as an ISR node—enabling enhanced maritime domain awareness and autonomous collaboration across surface, subsurface, and aerial platforms. Built with mission-driven design, Merrows™ now delivers ...

Core Viewpoint - Nuwellis, Inc. has signed a non-binding letter of intent to acquire Rendiatech, Ltd., aiming to enhance its fluid management technology offerings, particularly in continuous renal health monitoring [1][3]. Company Overview - Nuwellis, Inc. is a medical technology company focused on improving patient outcomes through advanced fluid management, currently commercializing the Aquadex SmartFlow system for ultrafiltration therapy [7]. - Rendiatech, Ltd. specializes in real-time urine flow and acute kidney injury monitoring technologies, with its key product being the Clarity RMS, an FDA-cleared critical care monitoring system [6]. Proposed Acquisition Details - The acquisition will potentially add Rendiatech's Clarity RMS and the next-generation Clarity Prime system to Nuwellis' product portfolio, enhancing real-time urine monitoring capabilities [2][5]. - The transaction is expected to close in the fourth quarter of 2025, pending due diligence and final Board approval [5]. Strategic Importance - The acquisition aligns with Nuwellis' growth strategy to achieve cash flow positivity and enhance its comprehensive fluid management offerings [3]. - Real-time urine output monitoring is critical for detecting acute kidney injury (AKI), which affects 10% to 20% of emergency hospital admissions, with higher rates in ICU settings [4]. Market Impact - The integration of Rendiatech's technologies is anticipated to improve clinical outcomes through earlier detection of AKI and dehydration, particularly in complex ICU patients [4].